ERBB2 and breast cancer: Considering the observed pHER2Y877+ prevalence among HER2 negative BC patients in our study, we estimate that 1,080 BC patients were HER2−/pHER2Y877+ in Canada in 2019 and could have benefited from trastuzumab.